Baidu
map

来自日本的Nichi葡聚糖膳食补剂有望用作COVID-19疫苗佐剂

2021-03-10 国际文传 国际文传

《人类疫苗和免疫治疗学》发表论文显示,β葡聚糖能促进粘膜免疫、先天性免疫、适应性免疫和受训免疫

AFO-202黑酵母暗金黄担子菌株生产的β葡聚糖(Nichi葡聚糖)有望通过所有主要通路增强免疫,已被推荐值得作为COVID-19疫苗佐剂进行临床研究验证(https://doi.org/10.1080/21645515.2021.1880210)。通过鼻腔或口腔途径进入的病原体可通过唾液中的粘膜免疫和抗体来解决,而一旦进入体内,则通过先天性和适应性免疫系统以及受训的免疫力(TRIM)来解决。据国际疫苗学会相关科学期刊描述,Nichi葡聚糖可能通过上述所有方法产生有益作用。

Nichi葡聚糖作为疫苗佐剂:佐剂是通过增强或稳定疫苗来辅佐疫苗的制剂。具备免疫调节潜质的Nichi葡聚糖被认为更有优势,因为其对禽流感(H5N1、H5N2)疫苗的佐剂有效性(https://pubmed.ncbi.nlm.nih.gov/21532325/)已有报道,拥有自1996年以来在日本作为食品补剂食用的安全记录,人体研究记载的对整体健康的有益作用描述如下。

早先,GN Corporation的员工与单克隆抗体研究者Yoshikazu Kurosawa博士合作获得了流感中和抗体的专利,以识别适合疫苗接种的易感人群,1987年Susumu Tonegawa教授在其诺贝尔医学奖获奖感言中认可了该技术(https://www.nobelprize.org/uploads/2018/06/tonegawa-lecture.pdf)。

与病毒不同,人类缺乏有利突变其DNA或RNA的能力;因此,剩下的唯一选择就是增强自身免疫系统,以保护其免受不断进化的新病原体和不断突变的病毒的侵害。联名作者Gene Kurosawa博士表示,真菌极大地推动了人类健康,产生诸如青霉素的抗菌药和许多抗癌药,进一步研究该黑酵母看起来很有前景。有关Nichi葡聚糖通过平衡肠道菌群解决肠道营养不良的益生元潜质的临床研究正在进行中。

据报道,Nichi葡聚糖有望通过免疫系统的所有四条通路起作用,即粘膜免疫、适应性免疫、先天性免疫和受训免疫。对新型β葡聚糖的研究对于帮助找到增强人类免疫的方法至关重要,需牢记当前的Covid-19、突变型变异和未来的大流行。(图示:美国商业资讯)

据报道,Nichi葡聚糖有望通过免疫系统的所有四条通路起作用,即粘膜免疫、适应性免疫、先天性免疫和受训免疫。对新型β葡聚糖的研究对于帮助找到增强人类免疫的方法至关重要,需牢记当前的Covid-19、突变型变异和未来的大流行。(图示:美国商业资讯)

原文出处:http://www.businesswirechina.com/zh/news/45985.html

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1294606, encodeId=d2e2129460671, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316387, encodeId=d0d6131638e39, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350440, encodeId=41c1135044094, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947195, encodeId=702e94e19553, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 10 18:12:25 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1294606, encodeId=d2e2129460671, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316387, encodeId=d0d6131638e39, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350440, encodeId=41c1135044094, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947195, encodeId=702e94e19553, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 10 18:12:25 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-03-12 diushouji
  3. [GetPortalCommentsPageByObjectIdResponse(id=1294606, encodeId=d2e2129460671, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316387, encodeId=d0d6131638e39, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350440, encodeId=41c1135044094, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947195, encodeId=702e94e19553, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 10 18:12:25 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-03-12 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1294606, encodeId=d2e2129460671, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316387, encodeId=d0d6131638e39, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350440, encodeId=41c1135044094, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 12 04:00:28 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947195, encodeId=702e94e19553, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 10 18:12:25 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-03-10 jyzxjiangqin

    好文章!

    0

相关资讯

CELL:清华研究人员发现疫苗佐剂的可成药靶标

受到甲羟戊酸途径中断刺激免疫反应的临床观察所激发,来自清华大学药学院的研究人员假设该途径可作为疫苗佐剂发现的可成药靶标。

拓展阅读

CELL:清华研究人员发现疫苗佐剂的可成药靶标

受到甲羟戊酸途径中断刺激免疫反应的临床观察所激发,来自清华大学药学院的研究人员假设该途径可作为疫苗佐剂发现的可成药靶标。

Baidu
map
Baidu
map
Baidu
map